isabellemahe.bsky.social @isabellemahe.bsky.social · 23/05/2025How do you manage oral anticoagulants in patients undergoing an invasive dental procedure? Our prospective national study suggests a short DOAC discontinuation before the invasive dental procedure can minimize bleeding! @RPTHjournal doi.org/10.1016/j.rp... 031
Reposted by @isabellemahe.bsky.socialAmerican College of Cardiology @accintouch.bsky.social · 29/03/2025Extended anticoagulant therapy with reduced-dose apixaban was noninferior to full-dose in patients with active cancer and #cvVTE, based on findings from the API-CAT trial presented at #ACC25. Read the journal scan to learn more: bit.ly/43w2A8v #CardioSky #MedSky 087
Reposted by @isabellemahe.bsky.socialNEJM.org @nejm.org · 29/03/2025In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full results: nej.md/41YkRZK #ACC25 | @accintouch.bsky.social 1188
Reposted by @isabellemahe.bsky.socialNEJM.org @nejm.org · 13/04/2025In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full trial results and Research Summary: nej.md/41YkRZK #MedSky 0216
isabellemahe.bsky.social @isabellemahe.bsky.social · 14/04/2025#API-CAT study by the #nejm.org. #accintouch.bsky.social #isth.org #apixaban #VTE #cancer 000
Reposted by @isabellemahe.bsky.socialNEJM.org @nejm.org · 12/04/2025Patients with cancer and VTE are at risk for VTE recurrence, and there are limited data on appropriate and effective anticoagulation regimens beyond 6 months. Findings from the API-CAT trial are summarized in a short video.youtu.beReduced-Dose Apixaban for Cancer-Associated VTE (API-CAT Trial) | NEJMPatients with cancer and VTE are at risk for VTE recurrence, and there are limited data on appropriate and effective anticoagulation regimens beyond 6 months... 0146
isabellemahe.bsky.social @isabellemahe.bsky.social · 14/04/2025#API-CAT study by the @nejm.org. @accintouch.bsky.social @isth.org #apixaban #VTE #cancer 010
Reposted by @isabellemahe.bsky.socialDr Martha Gulati @drmarthagulati.bsky.social · 29/03/2025#APICAT trial at #ACC25 #LBCT #cardioonc 🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE 🩸more than half female! 👏🏽👏🏽 🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed 🩸no increase in deaths 33020
Reposted by @isabellemahe.bsky.socialInstitut du Cancer AP-HP. Nord @cancerparisnord.bsky.social · 01/04/2025Une étude majeure dans la prise en charge des patients atteints de cancer et traités pour un événement thromboembolique veineux, deuxième cause de décès, a été menée et coordonnée par la Pr Isabelle Mahé, cheffe du service de médecine interne de @hoplouismourier.bsky.social A découvrir ici 👇 041
Reposted by @isabellemahe.bsky.socialAssistance Publique – Hôpitaux de Paris (AP-HP) @ap-hp.bsky.social · 31/03/2025🔬 Pour la première fois, une étude démontre que la dose réduite d'un anticoagulant oral est aussi efficace que la dose pleine et réduit le risque hémorragique de 25% pour les patients atteints de #cancer traités pour thrombose veineuse ou embolie pulmonaire Découvrez les résultats 👉 swll.to/sOSmEZC 064
Reposted by @isabellemahe.bsky.socialjeanconnorsmd.bsky.social @jeanconnorsmd.bsky.social · 29/03/2025@acc25.bsky.social Isabelle Mahe presents API-CAT Low dose Apixaban noninferior to high dose for recurrent VTE and superior for lower bleeding-another win! 093
Reposted by @isabellemahe.bsky.socialJACC Journals @jaccjournals.bsky.social · 29/03/2025Dr. Isabelle Mahe on the extended anticoagulant treatment with a reduced versus full dose #apixaban in patients with cancer-associated #VTE #ACC25 #JACCJournals #APICAT #CardioOnc #cvCoag #CardioSky 174
isabellemahe.bsky.social @isabellemahe.bsky.social · 01/04/2025@acc2025.bsky.social @jaccjournals.bsky.social 021
isabellemahe.bsky.social @isabellemahe.bsky.social · 01/04/2025The article published in the @NEJM.org can be accessed.see below Citation: Mahé I, Carrier M, Didier M, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. NEJM. Published online March 29, 2025. Doi: 10.1056/NEJMoa2416112 021
Reposted by @isabellemahe.bsky.socialMarc Carrier, MD @marccarriermd.bsky.social · 29/03/2025Prof. @isabellemahe.bsky.social presents API-CAT at @accintouch.bsky.social published in @nejm.org: Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in cancer patients www.nejm.org/doi/full/10.... 0109
Reposted by @isabellemahe.bsky.socialRPTH @rpth.bsky.social · 02/03/2025Regulatory agencies have issued warnings about JAK inhibitors and VTE risk—but what does the evidence actually say? Our latest review breaks down the data, limitations, and next steps. @davidmsmadja.bsky.social @isabellemahe.bsky.social 📑 Read now: buff.ly/4ijJQNq 055
isabellemahe.bsky.social @isabellemahe.bsky.social · 26/02/2025The #VTE risk associated with #JAKi in #inflammatory diseases has been suggested, followed by precautionary measures by health authorities. This literature review illustrates that available data on VTE risk on JAKi are conflicting and inconclusive @DavidMSmadja @RPTHjournal doi.org/10.1016/j.rp... 032
